{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:10:01Z","timestamp":1774451401167,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-023-05315-4","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T09:02:57Z","timestamp":1679648577000},"page":"841-848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison between methotrexate and apremilast in Psoriatic Arthritis-a single blind randomized controlled trial (APREMEPsA study)"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1549-802X","authenticated-orcid":false,"given":"Joydeep","family":"Samanta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9727-044X","authenticated-orcid":false,"given":"GSRSNK","family":"Naidu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3917-1977","authenticated-orcid":false,"given":"Arghya","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5082-4954","authenticated-orcid":false,"given":"Amal","family":"Basnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0464-2989","authenticated-orcid":false,"given":"Tarun","family":"Narang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-0694","authenticated-orcid":false,"given":"Varun","family":"Dhir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9912-0085","authenticated-orcid":false,"given":"Sunil","family":"Dogra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0141-7655","authenticated-orcid":false,"given":"Sanjay","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0813-1243","authenticated-orcid":false,"given":"Aman","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"5315_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaad.2005.03.046","volume":"53","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM, Gladman DD, Mease PJ et al (2005) Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53:573. https:\/\/doi.org\/10.1016\/j.jaad.2005.03.046","journal-title":"J Am Acad Dermatol"},{"key":"5315_CR2","first-page":"1167","volume":"34","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Strand V et al (2007) Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 34:1167\u20131170","journal-title":"J Rheumatol"},{"key":"5315_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4103\/0378-6323.125472","volume":"80","author":"R Kumar","year":"2014","unstructured":"Kumar R, Sharma A, Dogra S (2014) Prevalence and clinical patterns of psoriatic arthritis in Indian patients with psoriasis. Indian J Dermatol Venereol Leprol 80:15\u201323. https:\/\/doi.org\/10.4103\/0378-6323.125472","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"6","key":"5315_CR4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700\u2013712. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"5315_CR5","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/rheumatology\/41.12.1457","volume":"41","author":"A Kumar","year":"2002","unstructured":"Kumar A, Malaviya AN, Pandhi A, Singh R (2002) Validation of an Indian version of the Health Assessment Questionnaire in patients with rheumatoid arthritis. Rheumatology (Oxford) 41(12):1457\u20131459. https:\/\/doi.org\/10.1093\/rheumatology\/41.12.1457","journal-title":"Rheumatology (Oxford)"},{"key":"5315_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels MM, Aletaha D, Alasti F, Smolen JS (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75:811\u2013818. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207507","journal-title":"Ann Rheum Dis"},{"key":"5315_CR7","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/rheumatology\/key369","volume":"58","author":"SK Appani","year":"2019","unstructured":"Appani SK, Devarasetti PK, Irlapati RVP, Rajasekhar L (2019) Methotrexate achieves major cDAPSA response, and improvement in dactylitis and functional status in psoriatic arthritis. Rheumatology (Oxford) 58:869\u2013873. https:\/\/doi.org\/10.1093\/rheumatology\/key369","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"5315_CR8","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/acr.24134","volume":"72","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Gladman DD, Ogdie A et al (2020) treatment-to-target with apremilast in psoriatic arthritis: the probability of achieving targets and comprehensive control of disease manifestations. Arthritis Care Res (Hoboken) 72(6):814\u2013821. https:\/\/doi.org\/10.1002\/acr.24134","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"5315_CR9","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3899\/jrheum.191209","volume":"48","author":"A Ogdie","year":"2021","unstructured":"Ogdie A, Liu M, Glynn M et al (2021) Descriptive comparisons of the effect of apremilast and methotrexate monotherapy in oligoarticular psoriatic arthritis: the corrona psoriatic arthritis\/spondyloarthritis registry results. J Rheumatol 48(5):693\u2013697. https:\/\/doi.org\/10.3899\/jrheum.191209","journal-title":"J Rheumatol"},{"key":"5315_CR10","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates LC, Moverley AR, McParland L et al (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 386:2489\u20132498. https:\/\/doi.org\/10.1016\/S0140-6736(15)00347-5","journal-title":"Lancet"},{"key":"5315_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/ard.2011.152223","volume":"71","author":"A Baranauskaite","year":"2012","unstructured":"Baranauskaite A, Raffayov H, Kungurov NV et al (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 71:541\u2013548. https:\/\/doi.org\/10.1136\/ard.2011.152223","journal-title":"Ann Rheum Dis"},{"key":"5315_CR12","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Gladman DD, Collier DH et al (2019) Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized controlled phase III Trial. Arthritis Rheumatol 71:1112\u20131124. https:\/\/doi.org\/10.1002\/art.40851","journal-title":"Arthritis Rheumatol"},{"key":"5315_CR13","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","volume":"57","author":"AF Wells","year":"2018","unstructured":"Wells AF, Edwards CJ, Kivitz AJ et al (2018) Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology (Oxford) 57:1253\u20131263. https:\/\/doi.org\/10.1093\/rheumatology\/key032","journal-title":"Rheumatology (Oxford)"},{"key":"5315_CR14","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ et al (2014) Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73:1020\u20131026. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205056","journal-title":"Ann Rheum Dis"},{"key":"5315_CR15","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.3899\/jrheum.151376","volume":"43","author":"M Cutolo","year":"2016","unstructured":"Cutolo M, Myerson GE, Fleischmann RM et al (2016) A Phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol 43:1724\u20131734. https:\/\/doi.org\/10.3899\/jrheum.151376","journal-title":"J Rheumatol"},{"key":"5315_CR16","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","volume":"75","author":"CJ Edwards","year":"2016","unstructured":"Edwards CJ, Blanco FJ, Crowley J et al (2016) Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 75:1065\u20131073. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207963","journal-title":"Ann Rheum Dis"},{"key":"5315_CR17","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1136\/annrheumdis-2017-211568","volume":"77","author":"P Nash","year":"2018","unstructured":"Nash P, Ohson K, Walsh J et al (2018) Early and sustained efficacy with apremilast monotherapy in biological-na.ve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis 77:690\u2013698. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211568","journal-title":"Ann Rheum Dis"},{"key":"5315_CR18","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","volume":"51","author":"GH Kingsley","year":"2012","unstructured":"Kingsley GH, Kowalczyk A, Taylor H et al (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 51:1368\u20131377. https:\/\/doi.org\/10.1093\/rheumatology\/kes001","journal-title":"Rheumatology (Oxford)"},{"key":"5315_CR19","doi-asserted-by":"publisher","first-page":"e000669","DOI":"10.1136\/rmdopen-2018-000669","volume":"4","author":"DD Gladman","year":"2018","unstructured":"Gladman DD, Kavanaugh A, Gmez-Reino JJ et al (2018) Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1\u20133 studies. RMD Open 4:e000669. https:\/\/doi.org\/10.1136\/rmdopen-2018-000669","journal-title":"RMD Open"},{"key":"5315_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/1759720X16673786","volume":"9","author":"M Reed","year":"2017","unstructured":"Reed M, Crosbie D (2017) Apremilast in the treatment of psoriatic arthritis: a perspective review. Ther Adv Musculoskelet Dis 9:45\u201353. https:\/\/doi.org\/10.1177\/1759720X16673786","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"11","key":"5315_CR21","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1007\/s10067-021-05774-9","volume":"40","author":"CG Gialouri","year":"2021","unstructured":"Gialouri CG, Fragoulis GE (2021) Disease activity indices in psoriatic arthritis: current and evolving concepts. Clin Rheumatol 40(11):4427\u20134435. https:\/\/doi.org\/10.1007\/s10067-021-05774-9","journal-title":"Clin Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05315-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-023-05315-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05315-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:26:25Z","timestamp":1744212385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-023-05315-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["5315"],"URL":"https:\/\/doi.org\/10.1007\/s00296-023-05315-4","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]},"assertion":[{"value":"29 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors has any completing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was obtained from the Institutional Ethics Committee of Post Graduate Institute of Medical Education and Research, Chandigarh, India (Protocol No.-INT\/IEC\/2019\/2234), dated 15.10.2019 and a written informed consent was obtained from all individual participants involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable as doesn\u2019t contain any individual details.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}